Dosimetric Impact of Residual Intrafraction Motion in Gated MR-Guided Prostate SBRT With Focal Dose Intensification

Radiation therapy for cancer has long been a game of precision, where the goal is to deliver a lethal dose to a tumor while sparing the healthy tissue surrounding it. For prostate cancer, a common and highly treatable form of the disease, doctors have increasingly turned to a method called stereotactic body radiotherapy. This approach delivers very high doses of radiation in just a few sessions, rather than the many weeks of treatment used in the past. To make this safe, the radiation beam must be aimed with extreme accuracy, because the prostate sits right next to sensitive organs like the bladder and rectum. In recent years, a new technology has emerged that allows doctors to see the prostate in real time during treatment using magnetic resonance imaging, or MRI, inside the radiation machine. This allows them to adjust the plan if the organ moves and to shrink the safety margins around the target, which helps protect nearby healthy tissue even further. However, there is a growing interest in a more aggressive strategy: boosting the dose specifically to the most dangerous part of the tumor, known as the dominant lesion, while keeping the dose to the rest of the prostate lower. This focal boost offers a chance to cure the cancer more effectively, but it also makes the treatment incredibly sensitive to movement. If the prostate shifts even slightly while the beam is on, the tiny, high-dose spot might miss its mark, leaving the cancer under-treated or the healthy tissue over-exposed.

A team of researchers at MD Anderson Cancer Center set out to understand exactly how much this tiny movement matters when using the new MRI-guided machines for these high-precision, boosted treatments. They focused on a specific question: does the prostate move enough during a treatment session to cause the radiation dose to miss the intended target, even when the machine is designed to pause and wait if movement occurs? To find the answer, they looked back at the treatment records of thirty patients who had received this type of therapy. Each patient was treated in five sessions, giving the researchers a total of one hundred and fifty treatment sessions to analyze. The patients were treated with a machine that combines a linear accelerator with a powerful MRI scanner, allowing the doctors to watch the prostate move in real time. The machine is programmed to stop the radiation beam if the prostate moves outside a safe zone, a process called gating, and to restart only when the organ is back in the right place. The researchers wanted to know if this safety system was perfect, or if there were still small, residual movements that happened while the beam was on, and if those movements were enough to change the amount of radiation the tumor actually received.

The researchers reconstructed the actual dose of radiation each patient received by combining the machine's delivery logs with the continuous video of the prostate's movement. They did not just look at how far the prostate moved; they calculated exactly how that movement changed the dose distribution on the tumor. They found that while the gating system worked well, it was not perfect. The prostate did move while the beam was active, and this movement was not the same in every direction. The organ tended to drift more significantly in the up-down and front-back directions than it did from side to side. In fact, in nearly half of the treatment sessions, the prostate moved more than three millimeters in the up-down direction, a distance that is small to the human eye but significant for a tightly focused radiation beam. This movement was mostly a slow drift that happened over time, rather than sudden jerks.

The most important finding was that this movement had a much bigger impact on the small, high-dose boost area than on the larger prostate target. When the prostate moved, the radiation dose to the main tumor area dropped by a small amount, but the dose to the boosted, high-risk lesion dropped by two to three times as much. This is because the boosted area is smaller and sits in a steeper dose gradient, meaning a tiny shift can push part of the tumor out of the high-dose zone. The researchers calculated that for the boosted area, the average dose dropped by about one percent, and the volume of the tumor receiving the full intended dose dropped by nearly six percent. While these numbers might sound small, in the world of cancer treatment, missing even a small portion of the tumor with the full dose can reduce the chance of a cure. The study confirmed that the current safety margins, which are designed to account for movement, were not quite large enough to fully protect this tiny, high-risk spot in every single session.

To solve this, the researchers used their data to design new, custom safety margins specifically for this type of treatment. Instead of adding the same amount of space around the tumor in every direction, they proposed adding more space in the directions where the prostate moves the most: the back and the bottom. They calculated that adding about two millimeters of extra space in the back and bottom directions, and slightly less in the other directions, would ensure that the tumor received the full dose in about ninety-four percent of the treatment sessions. They tested this idea by re-creating the treatment plans with these new, asymmetric margins and found that it successfully fixed the coverage problem without causing the radiation to spill over into healthy organs. However, there is a trade-off. Using these tighter, more precise margins means the machine has to pause more often to wait for the prostate to settle, which slightly lengthens the treatment time. The researchers estimated that this would reduce the time the beam is actually on by about seven percent, but they concluded that the benefit of ensuring the cancer receives the full dose outweighs the extra time in the chair.

This study highlights a critical gap in how we currently manage radiation therapy for prostate cancer. It shows that simply watching the organ move and stopping the beam when it gets too far away is not enough to guarantee that the most dangerous part of the tumor gets the full dose. The movement that happens while the beam is on, even if small, can leave a gap in the treatment. By using the detailed data from the MRI machine to reconstruct exactly what happened during treatment, the researchers were able to prove that the current methods need a slight adjustment. They demonstrated that by tailoring the safety margins to the specific way the prostate moves, doctors can make the treatment more robust. This approach ensures that the high-dose boost, which is designed to improve the chances of a cure, actually reaches its target every time. The work suggests that future treatments should move away from one-size-fits-all safety zones and toward custom margins that account for the unique, directional nature of organ movement, balancing the need for precision with the practical reality of keeping the treatment efficient.